Pfizer reportedly to launch Avastin biosimilar in December
Pfizer is reportedly planning to launch Zirabev (bevacizumab-bvzr), its biosimilar Avastin (bevacizumab) on Dec. 31, according to a report from the Center for Biosimilars.
The launch date followed the settlement of patent litigation between Pfizer and Genentech and Roche over the biosimilar, which the Food and Drug Administration approved in June. The drug is indicated to treat various forms of cancer, including metastatic colorectal cancer, recurrent glioblastoma and various forms of cervical cancer, among others.
Currently, there is one other biosimilar bevacizumab available — Amgen’s Mvasi.